CJC-1295 NO DAC + Ipamorelin

The most studied secretagogue combination: a short-acting GHRH analog (CJC-1295 without DAC, also known as modified GRF 1-29) combined with the selective ghrelin receptor agonist ipamorelin.

GHRH receptor and GHS-R1a agonism act via different intracellular pathways on the same population of somatotrophs, and the ghrelin arm additionally suppresses somatostatin tone. In endocrinological studies this produces a larger GH pulse than either agent alone, while preserving physiological pulsatility, since the no-DAC variant is cleared within approximately 30 minutes.

Store the sealed lyophilized vial at 2-8 °C, protected from light; brief exposure to room temperature during shipping is generally tolerated. Refrigerate after reconstitution at 2-8 °C and use within the period supported by stability data for the substance (typically 2-4 weeks). Avoid repeated freeze-thaw cycles: each cycle increases the risk of aggregation and hydrolysis of the peptide bond. Do not shake the vial; swirl gently and direct the liquid stream against the glass wall rather than at the powder cake.

• Sealed lyophilized vial, stored as supplied
• Bacteriostatic water (0.9% benzyl alcohol) for reconstitution
• Insulin syringes (29-31G, 0.5 mL / 100 units)
• Reconstitution syringe (1-3 mL, 21-23G needle)
• 70% isopropyl alcohol swabs
• Sharps container for used needles
• Labels and a logbook for batch, date and volume

Reported outcomes are increases in GH pulse amplitude and downstream IGF-1 within physiological limits. Reported adverse effects include transient flushing, water retention, tingling in the extremities and injection-site reaction. Sustained IGF-1 elevation requires monitoring according to the clinical literature.

Wash your hands, then disinfect the vial septum and the injection site with 70% isopropyl alcohol and allow both to air dry. Draw up the intended volume, remove air bubbles and pinch a subcutaneous skin fold. Insert at a 45-90° angle depending on fat thickness, aspiration is not required for subcutaneous administration, and inject slowly. Withdraw the needle, apply light pressure and discard the needle in a sharps container. Rotate injection sites systematically (abdominal quadrants, flanks, thighs) to prevent lipohypertrophy and local irritation.

Peptide research protocols are studied against a background of adequate protein intake (approximately 1.6-2.2 g/kg/day in the training literature), consistent sleep of 7-9 hours, and controlled training load. Sleep deprivation and chronic psychological stress both dampen growth hormone pulsatility and disrupt tissue remodeling, complicating the interpretation of any observed effect. Alcohol, smoking and large caloric deficits are likewise documented modifiers of recovery outcomes.

1. Teichman S.L. et al. Prolonged stimulation of GH and IGF-1 by CJC-1295. J Clin Endocrinol Metab, 2006.
2. Raun K. et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 1998.
3. Sinha D.K. et al. Beyond the androgen receptor: growth hormone secretagogues. Transl Androl Urol, 2020.